

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 March 2025 (06.03.2025)



(10) International Publication Number
WO 2025/045772 A1

(51) International Patent Classification:

C07D 209/16 (2006.01) *A61K 31/33* (2006.01)
A61P 25/06 (2006.01) *C07D 401/12* (2006.01)
A61P 25/18 (2006.01) *C07D 403/12* (2006.01)
A61P 25/22 (2006.01) *C07F 9/06* (2006.01)
A61P 25/24 (2006.01)

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2024/073713

(22) International Filing Date:

23 August 2024 (23.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/578,791 25 August 2023 (25.08.2023) US

(71) Applicant: **COMPASS PATHFINDER LIMITED**
[GB/GB]; 3rd Floor, 1 Ashley Road, Altrincham Cheshire
WA14 2DT (GB).

(72) Inventors: **MORPHY, John Richard**; c/o COMPASS
Pathfinder Limited, 3rd Floor, 1 Ashley Road, Altrincham
Cheshire WA14 2DT (GB). **BAKER, Thomas Matthew**;
Pennyfoot Street, Sygnature Discovery, BioCity, Notting-
ham Nottinghamshire NG1 1GR (GB). **BROWN, Andrew**
William; Pennyfoot Street, Sygnature Discovery, BioCity,
Nottingham Nottinghamshire NG1 1GR (GB).

(74) Agent: **COOLEY (UK) LLP**; 22 Bishopsgate, London
Greater London EC2N 4BQ (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-YL DERIVATIVES



(57) Abstract: Provided herein are compounds of Formula (I), a compound selected from any of the compounds in Table 1, Table 2, Table 3, or a pharmaceutically acceptable salt or deuterated form thereof, wherein R^1 , R^2 , R^3 and R^4 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I), or a compound selected from any of the compounds in Table 1, Table 2, Table 3, or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of formula (I) or pharmaceutically acceptable salt or deuterated form thereof, e.g., in treating 5-HT_{2A} receptor associated (I) diseases or disorders.



WO 2025/045772 A1